Literature DB >> 9592619

Pharmacokinetics and pharmacodynamics of hydroxyurea.

P R Gwilt1, W G Tracewell.   

Abstract

Hydroxyurea is used in the treatment of various forms of cancer, sickle-cell anaemia and HIV infection. Oral absorption of the drug is virtually complete, the volume of distribution is equivalent to total body water and elimination is through both renal and nonrenal mechanisms. Nonrenal elimination of hydroxyurea is characterised by Michaelis-Menten kinetics. Further studies are necessary to clarify several aspects of the pharmacokinetics and pharmacodynamics of hydroxyurea: the effect of age and disease state, concentration-effect relationship, the role of therapeutic drug monitoring, and the mechanisms of renal and nonrenal elimination. The recent development of improved assays for hydroxyurea should have benefits for future pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9592619     DOI: 10.2165/00003088-199834050-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  70 in total

Review 1.  Laboratory and clinical studies of biochemical modulation by hydroxyurea.

Authors:  R L Schilsky; M J Ratain; E E Vokes; N J Vogelzang; J Anderson; B A Peterson
Journal:  Semin Oncol       Date:  1992-06       Impact factor: 4.929

2.  Hydroxyurea therapy in chronic myelogenous leukemia.

Authors:  B J Kennedy
Journal:  Cancer       Date:  1972-04       Impact factor: 6.860

3.  Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors.

Authors:  I M Ariel
Journal:  Cancer       Date:  1970-03       Impact factor: 6.860

4.  Evidence for the involvement of cytochrome P-450-dependent monooxygenase(s) in the formation of genotoxic metabolites from N-hydroxyurea.

Authors:  U Andrae
Journal:  Biochem Biophys Res Commun       Date:  1984-01-30       Impact factor: 3.575

5.  Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma.

Authors:  R L Schilsky; S F Williams; J E Ultmann; S Watson
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

6.  Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.

Authors:  M J Ratain; R L Schilsky; B R Wojack; T Simon; E K Senekjian; N J Vogelzang
Journal:  J Natl Cancer Inst       Date:  1988-11-02       Impact factor: 13.506

7.  Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.

Authors:  W Y Gao; D G Johns; S Chokekuchai; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

8.  Characterization of the free radical of mammalian ribonucleotide reductase.

Authors:  A Gräslund; A Ehrenberg; L Thelander
Journal:  J Biol Chem       Date:  1982-05-25       Impact factor: 5.157

9.  Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.

Authors:  W P Vaughan; E Kris; J Vose; P J Bierman; P Gwilt; J O Armitage
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells.

Authors:  J Minford; D Kerrigan; M Nichols; S Shackney; L A Zwelling
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

View more
  23 in total

Review 1.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  A role for nitric oxide in hydroxyurea-mediated fetal hemoglobin induction.

Authors:  S Bruce King
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

3.  Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.

Authors:  Scott T Miller; Kathy Rey; Jin He; Jonathan Flanagan; Billie J Fish; Zora R Rogers; Winfred C Wang; Russell E Ware
Journal:  Pediatr Blood Cancer       Date:  2011-07-08       Impact factor: 3.167

Review 4.  Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.

Authors:  David Dingli; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

5.  Structure of the yeast ribonucleotide reductase Y2Y4 heterodimer.

Authors:  W C Voegtli; J Ge; D L Perlstein; J Stubbe; A C Rosenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 6.  Nucleotide metabolism, oncogene-induced senescence and cancer.

Authors:  Katherine M Aird; Rugang Zhang
Journal:  Cancer Lett       Date:  2014-01-29       Impact factor: 8.679

7.  Stable-Isotope Dilution HPLC-Electrospray Ionization Tandem Mass Spectrometry Method for Quantifying Hydroxyurea in Dried Blood Samples.

Authors:  Anu Marahatta; Vandana Megaraj; Patrick T McGann; Russell E Ware; Kenneth D R Setchell
Journal:  Clin Chem       Date:  2016-09-30       Impact factor: 8.327

8.  Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.

Authors:  Min Dong; Patrick T McGann; Tomoyuki Mizuno; Russell E Ware; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2016-02-05       Impact factor: 4.335

9.  Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics.

Authors:  Aisha L Walker; Cynthia S Lancaster; David Finkelstein; Russell E Ware; Alex Sparreboom
Journal:  Am J Physiol Cell Physiol       Date:  2013-08-28       Impact factor: 4.249

10.  Generation of nitroxyl by heme protein-mediated peroxidation of hydroxylamine but not N-hydroxy-L-arginine.

Authors:  Sonia Donzelli; Michael Graham Espey; Wilmarie Flores-Santana; Christopher H Switzer; Grace C Yeh; Jinming Huang; Dennis J Stuehr; S Bruce King; Katrina M Miranda; David A Wink
Journal:  Free Radic Biol Med       Date:  2008-05-03       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.